Gene-edited blood cell therapy for AML after transplant relapse
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase study tests a gene-editing approach that turns off CD33 in donated blood-forming cells, aiming to make CD33-targeted immunotherapy safer and more effective. It is for adults with AML that came back after an allogeneic (donor) stem-cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have AML confirmed by standard testing
- Your AML must have returned after a donor stem-cell transplant from a matched family donor (at least 2 months after transplant)
- At relapse, your bone marrow blast level must be 29% or less
- Your leukemia cells must have CD33 on them, confirmed by a specific lab test (flow cytometry)
- Your body must have enough organ function (kidney, liver, lungs, and heart) for the planned treatment
- You cannot have certain conditions like active serious infections, HIV, or pregnancy/breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of immune cell called gamma-delta T cells in people with acute myeloid leukemia who still have minimal residual disease after a stem cell transplant. The goal is to see if these cells can clear the remaining leukemia cells safely and effectively.
This trial tests a new approach for people with acute myeloid leukemia (AML) that has not gotten better with standard treatments. First, you receive modified stem cells, then specially designed immune cells (CAR T cells) that target a protein called CD33 on leukemia cells. The goal is to see if this combination can safely help your body fight the leukemia.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
This study compares standard chemotherapy to chemotherapy plus CPX-351 and/or gilteritinib in children and young adults newly diagnosed with AML. It aims to see whether adding these targeted treatments improves outcomes, especially for certain gene changes like FLT3.
This trial tests a new gene therapy that edits your own blood stem cells to help them make more fetal hemoglobin, which can prevent sickling and reduce the need for transfusions. It is for people with severe sickle cell disease or beta thalassemia who do not have a matched sibling donor.
Hear when a new Relapsed/Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.